AbbVie to acquire Aliada Therapeutics for $1.4bn.

AbbVie, an American pharmaceutical company headquartered in North Chicago, Illinois, agreed to acquire Aliada Therapeutics, a biotechnology company focused on addressing delivery challenges in CNS drug development, for $1.4bn. "Neuroscience is one of our key growth areas and we are committed to driving innovation in this field to address critical unmet needs for patients living with seriously debilitating neurological diseases such as Alzheimer's disease. This acquisition immediately positions us to advance ALIA-1758, a potentially best-in-class disease-modifying therapy for Alzheimer's disease. In addition, Aliada's novel BBB-crossing technology strengthens our R&D capabilities to accelerate the development of next-generation therapies for neurological disorders and other diseases where enhanced delivery of therapeutics into the CNS is beneficial," Roopal Thakkar, AbbVie executive vice president, research and development and chief scientific officer.